All adults with endocrine disorders should be tested for high cholesterol and triglycerides to evaluate their risk of heart attack or stroke, according to a Clinical Practice Guideline issued today by the Endocrine Society.
International study may guide therapeutic strategies in patients with and without underlying heart conditions
Research from Saint Louis University finds that high fat or “ketogenic” diets could completely prevent, or even reverse heart failure caused by a metabolic process.
In a new multicenter study, researchers led by University of Utah Health physicians report that an emerging heart failure treatment could potentially reverse structural damage to the heart, allowing it to heal itself over time. Overall, 19 (40%) patients who were treated with a combination of LVAD support with heart failure medications had sufficient improvement that the LVAD could be removed.
• Adults with glomerular diseases have a 2.5-times higher risk of developing cardiovascular disease than individuals in the general population. • Results from the study will be presented online during ASN Kidney Week 2020 Reimagined October 19–October 25.
• A new model that incorporates a type of artificial intelligence can accurately predict which individuals with chronic kidney disease face a high risk of developing atrial fibrillation. • Results from the study will be presented online during ASN Kidney Week 2020 Reimagined October 19–October 25.
Treating lung cancer patients with proton therapy may help reduce the risk of radiation-induced heart diseases.
Two commonly used approaches to protect the brain during surgery to repair an ascending aortic aneurysm are equally effective, according to a review by University of Miami Miller School of Medicine researchers published October 6 in the Journal of Cardiac Surgery. Dr. Joseph Lamelas, pioneer of the minimally invasive approach to cardiac surgery, authors study.
A new national policy was created to make determining who receives a heart transplant more fair. But new data shows it changed some practice patterns, too.
The OPTIMIZE randomized trial comparing a novel, low-profile drug-eluting stent (DES) facilitating transradial access (TR) and direct stenting (DS) to existing DES did not establish non-inferiority of the new stent based on the prespecified study statistical analysis plan, likely due to the definition of periprocedural target vessel myocardial infarction (TVMI) coupled with a large proportion of high-sensitive cardiac troponin assays used in the trial.
A large subgroup analysis of a randomized clinical trial showed neither a mortality risk nor benefit associated with the use of paclitaxel drug-coated devices (DCD) in the treatment of peripheral artery disease (PAD). The study also found that the benefit of rivaroxaban use on reducing ischemic limb and cardiovascular outcomes was consistent regardless of whether a DCD was used.
For patients undergoing percutaneous coronary intervention (PCI) that also require oral anticoagulation, treatment with a nanotechnology polymer-coated stent plus 14-day dual anti-platelet therapy (DAPT) did not reduce bleeding or establish non-inferior outcomes for thrombotic events compared with a drug-eluting stent (DES) and standard three or six-month DAPT therapy.
A randomized clinical trial found that drug-eluting stents (DES) with durable polymers are non-inferior to DES with biodegradable polymers in patients with acute coronary syndrome (ACS). Findings were reported today at TCT Connect, the 32nd annual scientific symposium of the Cardiovascular Research Foundation (CRF). TCT is the world’s premier educational meeting specializing in interventional cardiovascular medicine.
The Cardiovascular Research Foundation (CRF) is pleased to announce that OnSight Medical, an AI-based company specializing in cardiac ultrasound imaging, has won the TCT 2020 Shark Tank Innovation Competition which took place during the Transcatheter Cardiovascular Therapeutics (TCT), the world’s premier educational meeting specializing in interventional cardiovascular medicine. The winner was also presented with the Jon DeHaan Foundation Award for Interventional Innovation.
A new observational study of deferred lesions following combined fractional flow reserve (FFR) and coronary flow reserve (CFR) assessments found that untreated vessels with abnormal FFR but intact CFR do not have non-inferior outcomes compared to those with an FFR greater than 0.8 and a CFR greater than or equal to two when treated medically.
Results from the randomized controlled TARGET FFR trial show that while a physiology-guided percutaneous coronary intervention (PCI) optimization strategy did not achieve a significant increase in the proportion of patients with final FFR ≥0.90, it reduced the proportion of patients with a residual FFR ≤0.80 following PCI.
In the FORECAST randomized clinical trial, the use of fractional flow reserve management derived from computed tomography (FFRCT) did not significantly reduce costs but did reduce the use of invasive coronary angiography (ICA).
The MITHRAS randomized clinical trial found that interventional closure of an iatrogenic atrial septal defect (iASD) driven by transcatheter mitral valve repair (TMVR) was not superior to conservative medical treatment with regard to the primary endpoint of change in six-minute walking distance.
The REFLECT II randomized clinical trial evaluating the safety and efficacy of a device designed to reduce cerebral embolization and ischemic stroke, complications of transcatheter aortic valve replacement (TAVR), found that the device met the primary safety endpoint compared to historical controls but did not demonstrate superiority of the device for the primary hierarchical efficacy endpoint.
In a randomized clinical trial, SCOPE II, a new self-expanding bioprosthetic valve used in transcatheter aortic valve replacement (TAVR) failed to demonstrate non-inferiority compared to an existing self-expanding valve.
RSS
Medicine keyboard_arrow_right
Sciencekeyboard_arrow_right
Life keyboard_arrow_right
Business keyboard_arrow_right
Journal News keyboard_arrow_right
By Location keyboard_arrow_right
Meetings, Grants, and Events keyboard_arrow_right